Celldex price target raised to $50 from $46 by Morgan Stanley
Morgan Stanley raised its price target on Celldex Therapeutics to $50.00 per share from $46.00. The stock is maintained at Overweight by Morgan Stanley, per Benzinga via TradingView News.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.